Skip to main content
Canna~Fangled Abstracts

Evidence for the use of cannabis-based medicines in osteoarthritis: a scoping review

By June 9, 2024June 12th, 2024No Comments

 

Review
. 2024 Jun 9.

doi: 10.1007/s10067-024-07001-7.

Online ahead of print.
Andrew T Y Xiao 1, Tarek Turk 2, Karanvir Deol 3, Susan Zhang 3 4, Heba A T Aref 4, Alexandra Campbell 3 4, Allyson Jones 5, Shelby S Yamamoto 6, Liz Dennett 7, Linda Kolewaski 3, Cheryl A Sadowski 8, Elaine A Yacyshyn 9
Affiliations 

Abstract

The purpose of this study was to conduct a scoping review to describe the evidence on the efficacy and safety of using cannabis-based medicines for osteoarthritis. The review was conducted following the framework proposed by Arksey and O’Malley and reported following PRISMA extension for scoping reviews guidelines. We conducted a comprehensive search across various databases including MEDLINE, Embase, Cochrane Library, CINAHL, Scopus, and Proquest, spanning from inception of each database to March 2023. We retrieved 2533 citations, and after deduplication, title and abstract screening, and full-text screening, 10 articles were included for analysis. These studies were composed of randomized-controlled trials (n = 4/10), cross-sectional surveys (n = 3/10), case studies (n = 2/10), and a cohort study (n = 1/10). Evidence for using cannabis-based medicines was mixed, with just 60% (n = 6/10) of included studies reporting statistically significant improvements in pain. Studies with larger samples sizes and longer durations of exposure did not find significant benefits for pain. The few adverse effects reported were generally mild and affected a minority of participants. Several studies also discovered that cannabis-based medicines were associated with a reduction in opioid use. Currently available data on the use of cannabis-based medicines in osteoarthritis is insufficient to make recommendations. Future research should address concerns regarding small sample sizes and short treatment durations to provide a more robust evidence base.

Key Points:

• Current evidence remains mixed; studies that found a positive benefit with using cannabis-based medicines had limitations with small sample sizes and short durations of exposure

• The use of cannabis-based medicines in osteoarthritis appears to be generally well tolerated, adverse effects are mild and experienced by a minority of participants

• Cannabis-based medicines may decrease the use of opioids in patients with osteoarthritis

• Future research should address the gaps in long-term efficacy and safety data.

Keywords: Cannabinoids, Cannabis, Osteoarthritis, Rheumatology, Scoping review, THC

PubMed Disclaimer

References

    1. Abramoff B, Caldera FE (2020) Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am 104(2):293–311. https://doi.org/10.1016/j.mcna.2019.10.007 – DOI – PubMed
    1. Mobasheri A, Batt M (2016) An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med 59(5):333–339. https://doi.org/10.1016/j.rehab.2016.07.004 – DOI – PubMed
    1. Berenbaum F (2013) Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 21(1):16–21. https://doi.org/10.1016/j.joca.2012.11.012 – DOI – PubMed
    1. O’Brien M, McDougall JJ (2018) Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids. Curr Opin Pharmacol 40(100966133):104–109. https://doi.org/10.1016/j.coph.2018.03.012 – DOI – PubMed
    1. Kolasinski SL et al (2020) 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 72(2):220–233. https://doi.org/10.1002/art.41142 – DOI – PubMed – PMC

Publication types

Grants and funding

LinkOut – more resources

  • Full Text Sources

    • full text provider logo

 

Leave a Reply